Welcome to our dedicated page for Regency Centers SEC filings (Ticker: REGCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Regency Centers's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Regency Centers's regulatory disclosures and financial reporting.
REG has a Form 144 notice indicating a planned sale of 8,000 shares of its common stock through Rockefeller Capital Management on the Nasdaq, with an aggregate market value of $616,240.00. The notice lists 14,055,940,159 shares of REG common stock outstanding.
The seller acquired 6,625 of these shares via a stock award on 01/14/2025, treated as compensation and paid on 02/14/2025, and 1,375 shares via a stock award on 02/09/2018, also as compensation. The signer represents they are not aware of undisclosed material adverse information about REG.
Regency Centers Corporation executive Michael J. Mas, EVP and CFO, reported a sale of company stock. On February 10, 2026, he sold 15,000 shares of Common Stock of Regency Centers Corp. at a price of $76.8501 per share. After this transaction, he beneficially owned 39,020 shares directly.
Regency Centers filed a notice under Rule 144 for a planned sale of restricted shares. The filing covers the potential sale of 26,000 shares of common stock through Merrill Lynch on NASDAQ, with an aggregate market value of 1,958,060 at the time indicated.
The shares were originally acquired from Regency Centers on 02/14/2025 as a stock bonus, meaning they were granted as compensation rather than purchased for cash. The filing states that the person for whose account the securities are to be sold represents that they are not aware of undisclosed material adverse information about the company’s current or prospective operations.
Regency Centers director Peter Linneman reported a routine stock-based compensation transaction. On February 4, 2026, he acquired 357 shares of common stock coded as an "A" (award) transaction. These shares represent director’s fees paid in stock under Regency’s Omnibus Incentive Plan. Following this award, he beneficially owns 53,600 shares of Regency Centers common stock held directly.
Regency Centers Corp director Karin Klein reported a stock-based compensation grant. On February 4, 2026, she acquired 428 shares of Regency Centers common stock, reported at a price of $0.00 per share, as director fees paid in stock under Regency's Omnibus Incentive Plan.
Following this grant, Klein beneficially owns 23,198 shares of Regency Centers common stock in direct ownership form. The filing reflects a routine equity compensation award rather than an open-market purchase or sale.
Regency Centers Corporation executive Nicholas Andrew Wibbenmeyer, West Regional President & CIO, reported an equity grant on a Form 4. He received 4,414 shares of restricted stock on February 3, 2026 at a stated price of $0 per share.
The filing shows he now beneficially owns 4,414 derivative securities, held directly. According to the footnote, these restricted shares vest 25% per year beginning February 3, 2027, meaning the award becomes earned gradually over four years.
Regency Centers Corp. executive Alan Todd Roth, Eastern Regional President and Chief Operating Officer, reported an equity award in the form of a restricted stock grant. On February 3, 2026, he received 4,414 restricted shares of common stock at a price of $0 per share, held directly.
The award is subject to a time-based vesting schedule. According to the footnote, the shares vest 25% per year beginning February 3, 2027, meaning the grant becomes fully vested over four years if the conditions are met.
Regency Centers Corp. reported a new equity award to its President and CEO, Lisa Palmer. On February 3, 2026, she received a restricted stock grant covering derivative securities tied to 17,934 shares of common stock at a price of $0 per share.
The filing notes these shares vest in stages, with 25% of the award vesting each year beginning on February 3, 2027. The grant is held directly by Palmer and represents stock-based compensation that increases her beneficial ownership as the shares vest over time.